Toxoplasma gondii apical membrane antigen-1
US6902926B1 · kind B1 · utility
3Cited by
3References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 9, 2001 |
| Grant date | Jun 7, 2005 |
| Priority date | — |
| Expiry date | Feb 23, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.